Drug Profile
Anti-B7-2 monoclonal antibody GL-1
Alternative Names: Anti-CD86 monoclonal antibody GL-1; GL-1Latest Information Update: 11 Nov 2003
Price :
$50
*
At a glance
- Originator Repligen
- Developer Repligen; Roche
- Class Antihyperglycaemics; Monoclonal antibodies
- Mechanism of Action CD86 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Transplant rejection; Type 1 diabetes mellitus
Most Recent Events
- 11 Nov 2003 Discontinued - Preclinical for Transplant rejection in USA (unspecified route)
- 11 Nov 2003 Discontinued - Preclinical for Type-1 diabetes mellitus in USA (unspecified route)
- 10 Aug 1998 No-Development-Reported for Transplant rejection in USA (Unknown route)